Payment overview · 2025
General Payments
$225.11
3 reported records · 3 companies
Healthcare provider profile · identity verified
Felipe A Del Valle, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI, FL · NPI 1174508717
Verified facts
What the public records show
CMS Open Payments records show Felipe A Del Valle, M.D. received $225.11 in general payments during 2025 across 3 reported records.
Medtronic, Inc. accounted for 48.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$110.03 | 48.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $100.32 | 44.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.76 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $225.11 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $110.03 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $100.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
123 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1229 | 339 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1084 | 313 |
| Levothyroxine Sodium | Levothyroxine Sodium | 722 | 184 |
| Metformin Hcl | Metformin Hcl | 716 | 185 |
| Losartan Potassium | Losartan Potassium | 682 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 673 | 197 |
| Omeprazole | Omeprazole | 578 | 164 |
| Metoprolol Succinate | Metoprolol Succinate | 488 | 132 |
| Folic Acid | Folic Acid | 476 | 110 |
| Eliquis | Apixaban | 456 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 427 | 120 |
| Escitalopram Oxalate | Escitalopram Oxalate | 423 | 107 |
| Famotidine | Famotidine | 393 | 116 |
| Alprazolam | Alprazolam | 357 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 322 | 94 |
| Azithromycin | Azithromycin | 321 | 235 |
| Gabapentin | Gabapentin | 293 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 290 | 80 |
| Furosemide | Furosemide | 271 | 75 |
| Trazodone Hcl | Trazodone Hcl | 271 | 76 |
| Fluticasone Propionate | Fluticasone Propionate | 262 | 109 |
| Temazepam | Temazepam | 255 | 37 |
| Telmisartan | Telmisartan | 241 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 67 |
| Lisinopril | Lisinopril | 231 | 58 |
| Sertraline Hcl | Sertraline Hcl | 228 | 58 |
| Simvastatin | Simvastatin | 228 | 66 |
| Alendronate Sodium | Alendronate Sodium | 225 | 63 |
| Memantine Hcl | Memantine Hcl | 210 | 51 |
| Clonazepam | Clonazepam | 209 | 32 |
| Glimepiride | Glimepiride | 205 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 193 | 56 |
| Montelukast Sodium | Montelukast Sodium | 190 | 49 |
| Carvedilol | Carvedilol | 185 | 54 |
| Atenolol | Atenolol | 180 | 46 |
| Donepezil Hcl | Donepezil Hcl | 177 | 48 |
| Meclizine Hcl | Meclizine Hcl | 159 | 52 |
| Methylprednisolone | Methylprednisolone | 152 | 131 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 150 | 43 |
| Finasteride | Finasteride | 149 | 37 |
| Lorazepam | Lorazepam | 146 | 31 |
| Synthroid | Levothyroxine Sodium | 145 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 136 | 35 |
| Ezetimibe | Ezetimibe | 135 | 41 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 124 | 75 |
| Farxiga | Dapagliflozin Propanediol | 123 | 32 |
| Cefdinir | Cefdinir | 116 | 91 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 114 | 102 |
| Dicyclomine Hcl | Dicyclomine Hcl | 110 | 46 |
| Allopurinol | Allopurinol | 108 | 30 |
| Buspirone Hcl | Buspirone Hcl | 101 | 27 |
| Valsartan | Valsartan | 100 | 28 |
| Benzonatate | Benzonatate | 99 | 68 |
| Glipizide | Glipizide | 99 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 98 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 44 |
| Jardiance | Empagliflozin | 87 | 26 |
| Potassium Chloride | Potassium Chloride | 87 | 28 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 86 | 21 |
| Xarelto | Rivaroxaban | 86 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 19 |
| Azelastine Hcl | Azelastine Hcl | 71 | 36 |
| Bumetanide | Bumetanide | 68 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 26 |
| Entresto | Sacubitril/Valsartan | 66 | 14 |
| Irbesartan | Irbesartan | 66 | 21 |
| Mupirocin | Mupirocin | 66 | 41 |
| Prednisone | Prednisone | 65 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 64 | 17 |
| Latanoprost | Latanoprost | 62 | 15 |
| Metformin Hcl Er | Metformin Hcl | 62 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 16 |
| Celecoxib | Celecoxib | 59 | 23 |
| Spironolactone | Spironolactone | 58 | 17 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 57 | 42 |
| Ozempic | Semaglutide | 57 | 12 |
| Mirtazapine | Mirtazapine | 56 | 15 |
| Nifedipine Er | Nifedipine | 56 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 55 | 55 |
| Enalapril Maleate | Enalapril Maleate | 54 | 14 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 51 | 13 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 51 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | 13 |
| Tradjenta | Linagliptin | 51 | 11 |
| Bupropion Xl | Bupropion Hcl | 49 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 14 |
| Acyclovir | Acyclovir | 44 | 28 |
| Tresiba Flextouch U-100 | Insulin Degludec | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 12 |
| Ciclopirox | Ciclopirox | 41 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 41 | 12 |
| Ketoconazole | Ketoconazole | 40 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | 12 |
| Metronidazole | Metronidazole | 40 | 35 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | 12 |
| Restasis | Cyclosporine | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 34 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 18 |
| Ibuprofen | Ibuprofen | 31 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 28 | 24 |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 12 |
| Ammonium Lactate | Ammonium Lactate | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 15 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Tadalafil | Tadalafil | 25 | suppressed |
| Timolol Maleate | Timolol Maleate | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 22 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 19 |
| Ssd | Silver Sulfadiazine | 22 | 15 |
| Colchicine | Colchicine | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 12 |
| Digoxin | Digoxin | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Pentoxifylline | Pentoxifylline | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 16 | 13 |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Naproxen | Naproxen | 16 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Pindolol | Pindolol | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Mupirocin | Mupirocin Calcium | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tobradex St | Tobramycin/Dexamethasone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $225.11 · 3 records | Medtronic, Inc. | FARXIGA, MICRA, WATCHMAN FLX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error